Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | HTR2C | P28335 | 3/20 | 0.34 |
| ▸ | ESR1 | P03372 | 3/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9562068 | 1.00 | RIPK1 (0.36) | RIPK1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4593881 | 0.91 | ESR1 (0.40) | TRPV1ESR1BCHEACHE | |
| SCHEMBL4593883 | 0.91 | ESR1 (0.40) | TRPV1ESR1BCHEACHE | |
| SCHEMBL17528231 | 0.91 | RIPK1 (0.38) | RIPK1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9406194 | 0.89 | RIPK1 (0.39) | RIPK1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9406197 | 0.89 | RIPK1 (0.39) | RIPK1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24170298 | 0.88 | RIPK1 (0.38) | RIPK1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9406005 | 0.88 | RIPK1 (0.38) | RIPK1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9405998 | 0.88 | RIPK1 (0.38) | RIPK1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9405737 | 0.88 | RIPK1 (0.38) | RIPK1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9933679-B2 | Birefringence improving agent, ferroelectric liquid crystal composition and liquid crystal display device using the agent, and compound | LC VISION, LLC (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160161817-A1 | BIREFRINGENCE IMPROVING AGENT, FERROELECTRIC LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE USING THE AGENT, AND COMPOUND | LC VISION, LLC | 2016-06-09 | — | — | US | disclosed |
| US-5248447-A | 2,3-difluorohydroquinone derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-09-28 | — | — | US | disclosed |
| EP-0332007-B1 | DERIVATIVES OF 2,3-DIFLUOROHYDROQUINONE | MERCK PATENT GmbH (DE) | 1992-11-25 | — | — | EP | disclosed |
| EP-0373186-A1 | DERIVATIVES OF 2,3-DIFLUOROHYDROQUINONE | MERCK PATENT GmbH (DE) | 1990-06-20 | — | — | EP | disclosed |
| WO-1989008637-A1 | DERIVATIVES OF 2,3-DIFLUOROHYDROQUINONE | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-09-21 | — | — | WO | disclosed |
| EP-0332007-A1 | Derivatives of 2,3-difluorohydroquinone | MERCK PATENT GmbH (DE) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160161817-A1 | BIREFRINGENCE IMPROVING AGENT, FERROELECTRIC LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE USING THE AGENT, AND COMPOUND | PYCARD, BIRC7, BIRC8 | RIPK1 376/4885PDE4A 1171/4885PDE4B 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.